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OBJECTIVE: The ideal solution for fluid management during neurosurgical procedures remains controversial.
The aim of this study was to compare the effects of a 7.2% hypertonic saline - 6% hydroxyethyl starch (HS-HES)
solution and a 6% hydroxyethyl starch (HES) solution on clinical, hemodynamic and laboratory variables during
elective neurosurgical procedures.
METHODS: Forty patients scheduled for elective neurosurgical procedures were randomly assigned to the HS-
HES group or the HES group. After the induction of anesthesia, patients in the HS-HES group received 250 mL of
HS-HES (500 mL/h), whereas the patients in the HES group received 1,000 mL of HES (1000 mL/h). The
monitored variables included clinical, hemodynamic and laboratory parameters. Chictr.org: ChiCTR-TRC-
12002357
RESULTS: The patients who received the HS-HES solution had a significant decrease in the intraoperative total
fluid input (p,0.01), the volume of Ringer’s solution required (p,0.05), the fluid balance (p,0.01) and their
dural tension scores (p,0.05). The total urine output, blood loss, bleeding severity scores, operation duration
and hemodynamic variables were similar in both groups (p.0.05). Moreover, compared with the HES group,
the HS-HES group had significantly higher plasma concentrations of sodium and chloride, increasing the
osmolality (p,0.01).
CONCLUSION: Our results suggest that HS-HES reduced the volume of intraoperative fluid required to maintain
the patients undergoing surgery and led to a decrease in the intraoperative fluid balance. Moreover, HS-HES
improved the dural tension scores and provided satisfactory brain relaxation. Our results indicate that HS-HES
may represent a new avenue for volume therapy during elective neurosurgical procedures.
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& INTRODUCTION
Intraoperative fluid management is a critical component
of perioperative care in neurosurgical practice (1). Patients
undergoing elective neurosurgical procedures sometimes
require large volumes of intravenous fluid to maintain
hemodynamic homeostasis during surgery. However, these
volumes may leave patients with an excessive fluid load
that increases risks for various complications such as the
formation of cerebral edema, which is detrimental during
neurosurgical procedures. The main goal of intraoperative
fluid management is to achieve hemodynamic homeostasis
via the administration of small fluid volumes while
avoiding fluid overload (2). Currently, increasing investiga-
tion into the ideal solution for volume therapy during
neurosurgical procedures is being conducted around the
world.
Since small volume resuscitation with hypertonic saline
(HS) in patients suffering from hemorrhage shock was first
described in the 1980s (3), HS with or without a colloid such
as dextran or hydroxyethyl starch (HES) has emerged as an
attractive alternative in fluid management in a variety of
surgical practices (4). For example, a wealth of evidence
from cardiac surgeries has shown that HS with or without a
colloid can exert significant beneficial effects in maintaining
hemodynamic stability and a positive fluid balance (5-9).
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Moreover, similar benefits from HS with or without HES
have also been demonstrated in aortic aneurysm surgery
(10-12) and abdominal hysterectomy (13,14). However, to
our knowledge in the clinical setting of neurosurgical
practice, HS is mainly used to control intracranial hyperten-
sion (ICP) due to its hyperosmolar nature (15), and little is
known about the possible role of HS-HES in intraoperative
fluid management during elective neurosurgical proce-
dures.
In the prospective randomized clinical study presented
here, we compared the effects of a 7.2% HS - 6% HES
solution (HS-HES) and a 6% HES solution (HES) in terms of
the clinical, hemodynamic and laboratory measurements in
patients undergoing elective neurosurgical procedures. Our
hypothesis was that HS-HES could reduce the volume of
intraoperative fluid required to maintain the patients
undergoing surgery and lower the dural tension during
the operation.
& MATERIALS AND METHODS
Study population
Approval for the study was obtained from the Ethics
Committee of Beijing Sanbo Brain Hospital, Capital Medical
University, and written informed consent was obtained
from all of the study participants. This study enrolled 40
consecutive American Society of Anesthesiologists (ASA)
ASA I-II patients scheduled for elective neurosurgical
procedures. The exclusion criteria were age ,18 years or
.80 years; clinical signs of significantly increased ICP such
as severe headache, blurred vision and/or papilledema;
history of cardiac, pulmonary and renal dysfunction; fluid
or electrolyte disturbances; preoperative coagulation dis-
orders; and preoperative treatment with diuretics and/or
osmotic agents. The protocol was registered at Chictr.org
(ChiCTR-TRC-12002357).
Anesthetic management
Patients were premedicated with intravenous midazolam
(0.05 mg/kg) 10 min before the induction of anesthesia.
General anesthesia was induced with intravenous fentanyl
(2 mg/kg), vecuronium bromide (0.1 mg/kg) and propofol
(2 mg/kg). After the induction of anesthesia, radial arterial
catheters and right internal jugular venous catheters were
inserted. After endotracheal intubation, the lungs were
mechanically ventilated with intermittent positive pressure
ventilation to maintain the end-tidal CO2 pressure at 4.0-
4.67 kPa (30-35 mmHg) during the operation. Anesthesia
was maintained with isoflurane (end-tidal minimum alveo-
lar concentration of 1-1.2%) combined with an intravenous
bolus of fentanyl or vecuronium if necessary.
Intraoperative fluid management
After stabilization at a steady hemodynamic state after the
induction of anesthesia, the patients were randomly
assigned to receive 250 mL of a 7.2% HS - 6% HES solution
(HS-HES group, 500 mL/h) or 1,000 mL of a 6% HES
solution (HES group, 1,000 mL/h) through a central venous
line. Both solutions were supplied by Fresenius Company
(Bad Homburg, Germany). All of the patients in both
groups were routinely given 250 mL of 20% mannitol over
10 min at 1 hr after the start of volume expansion. Ringer’s
solution was used as a maintenance fluid during the study
period at a rate targeted for maintaining the central venous
pressure (CVP) at 8-12 mmHg (10.7-16.0 cmH2O) and the
mean arterial pressure (MAP) at $65 mmHg. Packed red
blood cells (PRBC) were transfused if the hemoglobin
concentration fell below 10 g/L. No additional colloid was
used during the operation.
Measurements
For all of the patients, each set of measurements included
clinical, hemodynamic and laboratory measurements.
The clinical variables included the volumes of Ringer’s
solution and PRBC infused, intraoperative total urine output,
blood loss, operative duration, intraoperative bleeding sever-
ity score and dural tension score. The fluid balance was
calculated as the difference between the intraoperative total
input (randomized solution, 20% mannitol, Ringer’s solution
and PRBC) and the output (intraoperative total urine output
and blood loss). The blood loss was estimated according to the
difference between the volume of fluid collected in the
graduated suction bottles and surgical drapes and the volume
of any washout fluids used during the operation.
The intraoperative bleeding severity was assessed in a
blinded manner by the neurosurgeons according to the
following grading scale: I. Mild bleeding and no suctioning
of blood was required; II. Mild bleeding with occasional
suctioning required, but the surgical field was not obscured;
III. Moderate bleeding with frequent suctioning required,
and the bleeding obscured the surgical field after the suction
was removed; IV. Severe bleeding with constant suctioning
required, the bleeding appeared again before it was
removed by the suction and the surgical field was severely
obscured, making surgery impossible.
The dural tension was used to estimate the degree of
brain relaxation and was determined immediately after the
opening of the dura by the neurosurgeons who were
blinded to the group assignments. The dural tension scores
were assigned using the following scale as described by
Cold et al. (16) with a minor modification: I. Normal dural
tension: the neurosurgeon easily opened the dura mater; II.
Increased dural tension: the dura mater could be opened
without additional procedures to lower the ICP; III.
Markedly increased dural tension: additional procedures
were necessary to lower the ICP to open the dura mater.
The hemodynamic measurements included the heart rate
(HR), MAP (via the radial artery) and CVP (via the right
internal jugular vein), which were monitored continuously
using an anesthesia monitor (GE-Ohmeda S/5, USA). The
laboratory measurements consisted of the hemoglobin
concentration (Hb), platelet count (Plt), hematocrit (Hct),
coagulation parameters (prothrombin time (PT), activated
partial thromboplastin time (APTT) and fibrinogen concen-
tration (Fbg)), plasma electrolyte concentrations (sodium,
potassium, chloride and calcium) and osmolality. All of the
hemodynamic and laboratory measurements were docu-
mented before the HS-HES or HES infusion (T0) and then
again at 30 min (T1), 60 min (T2), 70 min (T3, following the
administration of mannitol), 120 min (T4) and 180 min (T5)
after the start of infusion.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). All of the data are
presented as the mean¡ SD. For the clinical parameters, the
differences between the HS-HES and HES groups were
analyzed using a x2 test or Fisher’s exact test (categorical
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variables), a Mann-Whitney U test (intraoperative bleeding
severity scores and dural tension scores) and an unpaired
Student’s t test (age, weight, operation duration, intrao-
perative total fluid input, volume of Ringer’s solution,
PRBC, total urine output, blood loss and fluid balance). For
variables with multiple measurements (hemodynamic and
laboratory variables), a repeated measures analysis of
variance was used to evaluate the effects of time and group
assignment, while two-way analysis of variance was used to
compare the difference within the groups. Significance was
established at p,0.05.
& RESULTS
As shown in Table 1, there were no significant differences
between the two groups with respect to demographic data
(age, sex, weight and surgical procedures).
With regard to the clinical measurements, the two groups
did not significantly differ by operation duration, volume of
PRBC, intraoperative total urine output, blood loss or
intraoperative bleeding severity scores (Table 2). The
percentages of patients who required a PRBC transfusion
in the HS-HES group and the HES group were 25% (5/20)
and 20% (4/20), respectively (Table 2). Compared with HES
infusion, HS-HES infusion reduced the total fluid input
(p,0.01, Table 2) and the volume of Ringer’s solution
(p,0.05, Table 2) required during the operation. Moreover,
the fluid balance of the HS-HES group was significantly
lower than the HES group (p,0.01, Table 2), and HS-HES
treatment also led to a significant decrease in the dural
tension scores compared with HES infusion (p,0.05,
Table 2).
The changes in HR, MAP and CVP were similar in both
groups during the study period (Table 3). Specifically, the
HR and CVP in both groups significantly increased after the
volume infusion and then decreased over time (Table 3),
whereas the MAP was lower at T4 and T5 than at T0 in each
group.
There were no significant differences between the groups
in terms of the Hb, Plt, Hct, PT, APTT and Fbg values and
the plasma potassium or calcium concentrations, but the
plasma levels of sodium and chloride and the osmolality
were markedly increased in the HS-HES group compared
with the HES group (Table 4). After the volume expansion,
the Hb, Plt, Hct and Fbg values and the plasma calcium
concentration in both groups decreased significantly by
varying degrees, while the PT and APTT values increased
significantly during the study period. The plasma potas-
sium concentration displayed biphasic changes with an
increase at the early time points and a decrease at the later
time points after HS-HES or HES infusion. Furthermore, in
the HS-HES group, the concentrations of plasma sodium
and chloride peaked immediately at the end of the HS-HES
infusion (T1) and remained higher than that of the HES
group throughout the study period. The plasma osmolality
was significantly higher after HS-HES infusion (T1-5) than
prior to HS-HES infusion (T0).
& DISCUSSION
In the present study, we compared the effects of HS-HES
and HES in terms of the clinical, hemodynamic and
laboratory measurements in patients undergoing elective
neurosurgical procedures. The main findings were as
follows: 1) Administration of 250 mL of HS-HES was as
efficacious as 1,000 mL of HES in maintaining hemody-
namic homeostasis during the operation. 2) HS-HES
treatment significantly reduced the intraoperative total fluid
input and the volume of Ringer’s solution required to
maintain the patients undergoing surgery and led to a
significant decrease in the intraoperative fluid balance. 3)
The majority of the reduction in total fluid input (61%) was
due to the difference in the volume of HES (1,000 mL) and
HS-HES (250 mL) initially administered. A reduction in the
administration of Ringer’s solution accounted for 39% of the
difference. 4) HS-HES infusion markedly reduced the dural
tension scores and provided more satisfactory brain relaxa-
tion for the operations. 5) HS-HES infusion significantly
increased the plasma concentrations of sodium and chloride
and increased the plasma osmolality. These findings
provide substantial evidence that the HS-HES solution is
an attractive choice for fluid management during neuro-
surgical procedures.
The ideal solution for intraoperative volume therapy is
controversial. In neurosurgical procedures, achieving hemo-
dynamic homeostasis by the administration of small fluid
volumes is of major interest for avoiding fluid overload. HS
has been used in the clinic for several decades; its osmotic
and volume-expanding properties make it effective as a
reliable solution for intraoperative volume therapy. Thus,
there is great interest in the use of HS during operations.
Moreover, HS is usually used in association with a colloid in
most research studies because a wealth of evidence has
Table 1 - Demographic data for the patients treated with
HS-HES (n= 20) or HES (n = 20).
HS-HES group HES group
Age (yrs) 39¡12 40¡13
Sex (M/F) 11/9 10/10
Weight (kg) 60¡10 58¡11
Brain lesion
Glioma 19 17
Meningioma 1 3
The data are presented as the mean¡ SD. HS-HES: 7.2% hypertonic saline
- 6% hydroxyethyl starch solution, HES: 6% hydroxyethyl starch solution.
Table 2 - Clinical parameters of the patients treated with
HS-HES (n= 20) or HES (n= 20).
HS-HES group HES group
Operation duration (min) 350¡129 360¡96
Total fluid input (mL) 4261¡674** 5498¡676
HS-HES 250 0
HES 0 1000
20% mannitol 250 250
Ringer’s solution 3687¡659* 4178¡639
PRBC 74¡141 70¡152
Percentage of patients requiring
a PRBC transfusion
25% (5/20) 20% (4/20)
Total urine output (mL) 1430¡572 1585¡653
Blood loss (mL) 591¡296 470¡245
Fluid balance (mL) 2240¡706** 3443¡553
Dural tension scores (Grade I/II/III) 14/5/1* 6/11/3
Bleeding severity scores
(Grade I/II/III/IV)
8/9/3/0 9/8/3/0
*p,0.05 versus the HES group,
**p,0.01 versus the HES group. The data are presented as the mean¡ SD.
PRBC: packed red blood cell.
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shown that a colloid such as HES can prolong the
hemodynamic efficiency of HS (17).
Previous studies on models of hemorrhagic shock have
indicated that HS infusion in a volume equivalent to 25% of
the total blood lost can restore hemodynamic stability
(18,19), whereas an HES infusion can replace the blood lost
for a volume expansion at close to a 1:1 ratio (20,21). In the
present study, our data showed that there were no
significant differences in the hemodynamic parameters
between the groups after the infusion of 250 mL of HS-
HES or 1,000 mL of HES, which corroborate the above
results. Moreover, our results indicated that HS-HES could
reduce the intraoperative total fluid input and the volume of
Ringer’s solution required to maintain the patients under-
going surgery, which was in agreement with the evidence
that HS can be used as the fluid for small-volume
resuscitation in patients with hypovolemic shock (22).
However, in the present study, the majority of the total
fluid input reduction was due to the initial fluid load. Thus,
because the magnitude of the hemodilution and CVP were
similar in the present study, we assumed that the volume of
the plasma expansion was similar in both groups in spite of
the different volumes of fluid administered. Multiple
mechanisms are involved in the volume-expanding proper-
ties of HS, including the compartment redistribution with
fluid shifts to the vascular bed (8), the positive effects on
cardiac output (23) and the hormonal and immunologic
effects (24). Fluid balance during an operation and the
postoperative period are of considerable importance to
organic function, especially to cerebral function in neuro-
surgical procedures. In the present study, we investigated
the effect of HS-HES on the fluid balance during surgery
and found that HS-HES infusion could significantly reduce
the intraoperative fluid balance. Although we did not collect
any data on the effect of HS-HES on the postoperative fluid
balance, the results from other authors have demonstrated
that a near-zero fluid balance was observed in patients who
were given an HS-dextran infusion 48 hrs after cardiac
surgery (8,25), which suggests that the maximal effect of HS-
HES on the reduction of the fluid balance might appear
Table 3 - Hemodynamic parameters of the patients treated with HS-HES (n= 20) or HES (n = 20).
Group Before infusion Time after HS-HES or HES infusion (min)
30 60 70 120 180
HR (beats/min) HS-HES 67¡10 71¡13 75¡12## 78¡13## 71¡14 73¡16#
HES 67¡13 68¡13 72¡15# 77¡15## 75¡11## 77¡13##
MAP (mmHg) HS-HES 76¡13 79¡14 74¡11 71¡11 67¡9## 68¡9##
HES 83¡16 78¡11 82¡10 78¡10 74¡11## 69¡11##
CVP (cmH2O) HS-HES 8¡3 11¡3
## 12¡3## 14¡3## 10¡4## 8¡3
HES 8¡2 12¡3## 12¡2## 13¡3## 9¡2## 9¡3##
#p,0.05 versus the measurement before infusion,
##p,0.01 versus the measurement before infusion. The data are presented as the mean¡ SD. HR: heart rate, MAP: mean arterial pressure, CVP: central
venous pressure.
Table 4 - Laboratory parameters of the patients treated with HS-HES (n= 20) or HES (n =20).
Group Before infusion Time after HS-HES or HES infusion (min)
30 60 70 120 180
Hb (g/L) HS-HES 129.1¡11.6 110.4¡10.4## 109.9¡11.4## 101.7¡11.0## 110.4¡11.8## 107.9¡14.1##
HES 138.8¡19.9 116.2¡18.7## 113.7¡29.0## 100.2¡16.7## 105.7¡17.9## 106.9¡19.5##
Plt (6107/L) HS-HES 208.2¡53.7 197.4¡43.7## 197.0¡45.1## 184.4¡43.3## 204.4¡48.0 200.2¡46.4
HES 220.4¡42.9 205.2¡37.6## 188.0¡36.0## 173.3¡37.7## 191.3¡38.9## 198.6¡49.3##
Hct (%) HS-HES 38.4¡3.2 33.0¡3.2## 32.8¡3.4## 30.6¡3.2## 33.3¡3.5## 32.5¡3.9##
HES 41.3¡5.0 34.7¡4.9## 32.5¡4.7## 30.3¡4.6## 31.7¡4.8## 32.3¡5.5##
PT (s) HS-HES 10.4¡0.9 12.0¡0.7## 11.9¡0.8## 12.2¡0.9## 11.8¡0.7## 12.0¡0.8##
HES 10.5 ¡0.7 11.8¡0.7## 12.2¡0.7## 12.7¡0.8## 12.2¡1.1## 12.2¡1.0##
APTT (s) HS-HES 26.3¡5.8 33.4¡7.1## 33.4¡8.0## 37.6¡9.4## 33.8¡7.7## 33.1¡8.5##
HES 24.3¡3.7 30.8¡4.9## 35.3¡7.0## 40.6¡8.7## 36.1¡6.9## 36.7¡7.1##
Fbg (g/L) HS-HES 2.0¡0.4 2.0¡0.7 1.8¡0.3 1.7¡0.3## 1.8¡0.3 1.8¡0.3
HES 2.0¡0.6 1.8¡0.6 1.6¡0.5## 1.5¡0.5## 1.7¡0.6## 1.6¡0.5##
Na+ (mmol/L) HS-HES 138.7¡2.7 152.5¡4.4**## 147.4¡2.7**## 137.7¡8.3** 141.9¡2.5**# 141.5¡2.5**#
HES 139.2¡2.5 139.2¡2.1 138.0¡4.8 131.4¡2.8## 134.8¡2.6## 136.3¡3.1##
Cl- (mmol/L) HS-HES 107.6¡1.4 122.4¡4.3**## 118.5¡3.2**## 113.3¡3.3**## 114.9¡3.0**## 116.0¡2.9**##
HES 106.3¡3.0 109.8¡2.2## 110.0¡3.6## 105.2¡2.4 107.3¡2.9 109.2¡3.3##
K+ (mmol/L) HS-HES 3.8¡0.3 3.5¡0.4## 4.1¡0.5## 4.3¡0.6## 4.8¡0.7## 4.4¡0.5##
HES 3.9¡0.3 3.7¡0.3## 3.8¡0.4 3.9¡0.5 4.3¡0.5## 4.3¡0.4##
Ca2+ (mmol/L) HS-HES 2.1¡0.1 1.9¡0.1## 1.9¡0.1## 1.8¡0.1## 1.9¡0.1## 1.9¡0.1##
HES 2.2¡0.1 1.9¡0.2## 1.8¡0.3## 1.7¡0.2## 1.8¡0.1## 1.9¡0.2##
Osm (mOsm/kg H2O) HS-HES 300.7¡5.8 323.5¡8.2**
## 316.5¡5.4**## 328.7¡8.7**## 320.9¡5.3**## 315.8¡5.8**##
HES 301.0¡5.7 300.1¡5.8 302.9¡6.0 313.5¡7.4## 306.7¡7.5## 307.1¡8.2##
**p,0.01 versus the HES group,
#p,0.05 versus the measurement before infusion,
##p,0.01 versus the measurement before infusion. The data are presented as the mean ¡ SD. Hb: hemoglobin concentration, Plt: platelet count, Hct:
hematocrit, PT: prothrombin time, APTT: activated partial thromboplastin time, Fbg: fibrinogen concentration, Osm: osmolality.
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during the postoperative period. Further studies investigat-
ing the effect of HS-HES on the postoperative fluid balance
in patients following neurosurgical procedures are needed.
In our study, we used dural tension scores as an
alternative tool to indirectly monitor ICP. We found that
HS-HES reduced the dural tension scores and provided
more satisfactory brain relaxation for the operation. In
clinical practice, the ICP is not measured routinely during
elective neurosurgical procedures (26), which is also a
limitation of our present study. Thus, dural tension scores
are always used to partially reflect the ICP in neurosurgical
research and to compare the various interventions because
evidence has shown a strong positive correlation between
the degree of cerebral swelling and ICP (16,27-29). In the
present study, the improvement in the dural tension scores
in the HS-HES group may have arisen from the effect of HS
on controlling the ICP. HS reduces ICP in various types of
intracranial diseases, particularly following head trauma
with increased ICP (30). This effect exerted by HS-HES
infusion can mainly be attributed to its hyperosmotic
properties. HS-HES infusion produces an osmotic gradient
between the intravascular and intracellular/interstitial
compartments when the blood-brain barrier is intact,
leading to a reduction of brain volume and therefore
reducing the ICP (31). Additional effects such as decreasing
the formation of CSF may also contribute to the reduction of
ICP arising from HS-HES infusion (32). Moreover, we found
that HS-HES may exert additional effects to control ICP
even among patients who had already received mannitol,
which corroborated the evidence suggesting that HS
remained effective for mannitol-resistant ICP. Opening the
dura mater is a critical moment during a craniotomy
because the swelling brain may protrude through the
craniotomy site, which can seriously jeopardize surgical
access and increase the risk of cerebral ischemia with a
possible worsening of the outcome (16,28). Therefore,
satisfactory brain relaxation, as reflected by a reduction in
the dural tension scores in the HS-HES group, facilitates the
surgical process and reduces the potential risk for poor
outcomes.
In the present study, we did not find a marked diuretic
effect after HS-HES infusion compared with HES infusion,
although some studies have shown that HS can act as a
diuretic (33). We speculated that HS-HES infusion signifi-
cantly increased the plasma osmolality, which stimulated
the release of antidiuretic hormones and led to the
absorption of free water by the kidneys (34). Further study
is needed to explain the effect of HS-HES on the hormones
regulating water metabolism.
Interference with blood coagulation is another important
issue that deserves attention during volume therapy (35). In
the present study, although the coagulation parameters in
both groups showed significant changes from the baseline
values, they were still within the clinically tolerated ranges,
which indicated that there was no or only slight coagulation
impairment after HS-HES infusion. The finding that there
was no significant difference in the intraoperative bleeding
severity scores between the two groups supported the above
conclusions.
Electrolyte abnormalities are common complications after
the infusion of hyperosmotic drugs (15). In the present
study, hypernatremia and hyperchloremia occurred imme-
diately after HS-HES infusion. Normal plasma sodium
levels were present at the end of study period, although
they were higher in the HS-HES group than in the HS
group. By contrast, the plasma chloride levels remained
higher than normal throughout the study period. In the later
study periods (T3-5), the plasma sodium and chloride
concentrations showed transient decreases in comparison
with those concentrations at T2 before they gradually
increased. In the present study, the blood sample taken
after the administration of mannitol (T3) was analyzed
because previous studies had indicated that mannitol can
provide a transient volume expansion and subsequent
diuretic action (27), which may explain the changes in the
plasma concentrations of sodium and chloride at T3-5. The
plasma potassium concentrations in both groups displayed
biphasic changes with increases at the earlier time points
and decreases at the later time points. The concentrations
never exceeded the normal clinical range, which might be
due to the multiple additive effects such as hemodilution
from volume expansion at the earlier time points and the
diuretic effect from the mannitol at the later time points.
Moreover, we found that the plasma calcium concentration
decreased in both groups. Two reasons may account for the
hypocalcaemia: intraoperative bleeding can lead to the loss
of calcium; and hemodilution occurred from the volume
expansion of the HS-HES or HES treatments, which did not
contain calcium. However, even though no neurologic
deficits were found in the present study, it is still necessary
to monitor the electrolyte concentrations when an HS-HES
solution is infused. Not surprisingly, a clear increase in
plasma osmolality was observed after the HS-HES infusion
but not after the HES infusion. This increase is one of the
known mechanisms involved in the beneficial effects of HS-
HES treatment.
In conclusion, a 7.2% HS - 6% HES solution infused after
the induction of anesthesia is an attractive choice for fluid
management during neurosurgical procedures. HS-HES
infusion can reduce the volume of intraoperative fluid
required to maintain the patients undergoing surgery and
can lead to a decrease in the intraoperative fluid balance.
Furthermore, the majority of the total fluid input reduction
(61%) was due to the difference in the volume of HES
(1,000 mL) and HS-HES (250 mL) initially administered. A
reduction in the administration of Ringer’s solution
accounted for 39% of the difference. Moreover, HS-HES
decreased the dural tension scores and provided satisfac-
tory brain relaxation. Our results indicate that HS-HES may
represent a new avenue for volume therapy during
neurosurgical procedures.
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